RudaCure, a domestic company specializing in sensory disorder treatment development, announced the completion of its Japanese patent registration for non-narcotic analgesic technology targeting TRPV1 (Transient Receptor Potential Vanilloid 1). This Japanese patent registration is considered an important milestone in protecting the intellectual property rights of RudaCure's core technology. Currently, the same foundational patent has been filed in major markets including China, the US, and Europe, with Japan being the first to complete registration.
The TRPV1 antagonist-based analgesic being developed by RudaCure is attracting attention as a next-generation pain treatment solution that can address the addiction and side effects of existing narcotic analgesics. TRPV1 is an ion channel that plays a crucial role in pain signal transmission, and by selectively inhibiting it, powerful analgesic effects can be achieved without side effects. RudaCure, a domestic neurodegenerative disease startup, is researching antagonist-based analgesic drugs that can directly inhibit TRPV1 activity, and is expanding its drug development pipeline through joint research with Gachon University College of Medicine and global CROs.
An industry insider explained that "The completion of Japanese patent registration is significant in that it expands intellectual property protection for RudaCure's core technology into the world's third-largest pharmaceutical market," adding that "Japan is one of the world's largest markets for pain treatments and ophthalmic drugs, and this patent registration can serve as an important foundation for future licensing and partnership strategies."
RudaCure's TRPV1 modulation technology is applicable not only to pain treatment but also to ophthalmic disease treatment such as dry eye disease, showing potential to generate value across multiple therapeutic areas. The company's lead pipeline, dry eye disease treatment RCI001, has recently obtained U.S. FDA Phase 2 IND approval, and plans to expand the scope of patent protection for its core compound, which also demonstrates analgesic efficacy. Japan is a major market for pharmaceutical development, and this patent registration is expected to serve as a strategic bridgehead for Japanese domestic licensing and co-development partnerships. RudaCure plans to proceed with patent registrations in China, the US, and Europe, and will continue to strengthen its intellectual property portfolio.